Update: 12th April 2017
A revised statement has now also been issued by MEDA the UK distributer of EpiPen 12th April 2017
Meda Provides Update on Meridian Medical Technologies’, a Pfizer Company,
Expanded Voluntary Worldwide Recall of EpiPen® Auto-Injector
Meridian Medical Technologies, a Pfizer company and Meda’s manufacturing partner for EpiPen® Auto-Injector, has expanded a voluntary recall of select lots of EpiPen® and EpiPen Jr® Auto-Injectors. The situation has been reviewed by the MHRA, and in this instance, no recall is required for any EpiPen® batches within the UK.
The recall currently underway in several other markets is being conducted as a result of the receipt of two previously disclosed reports of failure to activate the device due to a potential defect in a supplier component. The potential defect could make the device difficult to activate in an emergency (failure to activate or increased force needed to activate) and have significant health consequences for a patient experiencing a life-threatening allergic reaction (anaphylaxis).
Both reports are related to the single lot that was previously recalled elsewhere, however the specific batch had not been distributed in the United Kingdom. The incidence of the defect is extremely rare and testing and analysis across the potentially impacted lots has not identified any units with a defect.
Should you receive any questions related to the recall, please direct them to firstname.lastname@example.org.
Update 11th April 2017
The Anaphylaxis Campaign has been in communication with the MEDA and the MHRA. Please see the latest the statement’s below.
The latest MHRA statement is below:
“We are aware of a precautionary recall of a number of batches of EpiPen following two reports of faults. There is currently no recall in the UK. We are in contact with the company, and are monitoring the situation in the UK closely.
There have been no reports in the UK of EpiPen failing to provide a dose. In line with existing medical guidelines, it is advised patients continue to carry two pens at all times”.
The Anaphylaxis Campaign is in constant communication with MEDA regarding the status of EpiPens in the UK.
We will let you know immediately if this status changes.
Please contact our helpline if you have any questions or concerns – 01252 542029, email@example.com
The MHRA is the government organisation regulating medicines, medical devices and blood components for transfusion in the UK.